Publication: The effect of peripherally administered cdp-choline in an acute inflammatory pain model: The role of α7 nicotinic acetylcholine receptor
dc.contributor.author | Parker, Renee | |
dc.contributor.author | Eisenach, James C. | |
dc.contributor.author | Vincler, Michelle | |
dc.contributor.buuauthor | Gürün, Mine Sibel | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.department | Farmakoloji ve Klinik Farmakoloji Ana Bilim Dalı | |
dc.contributor.researcherid | AAG-8716-2019 | |
dc.contributor.scopusid | 55664349700 | |
dc.date.accessioned | 2021-11-17T12:57:45Z | |
dc.date.available | 2021-11-17T12:57:45Z | |
dc.date.issued | 2009-05 | |
dc.description.abstract | BACKGROUND: CDP-choline (citicholine; cytidine-5'-diphosphate choline) is an endogenously produced nucleotide which, when injected intracerebroventricularly, exerts an antinociceptive effect in acute pain models mediated by central cholinergic mechanisms and alpha 7 nicotinic acetylcholine receptors (alpha 7nAChR). Previous reports also suggest that the peripheral cholinergic system has an antiinflammatory role mediated by alpha 7nAChRs on macrophages. METHODS: We used male Sprague-Dawley rats to assess the antihypersensitivity and antiinflammatory effect of CDP-choline after intraplantar injection of carrageenan (100 mu L, 2%). Mechanical paw withdrawal thresholds and paw thickness were measured by Randall-Selitto testing and microcallipers, respectively. All drugs were administered intraplantarly in a volume 50 mu L. RESULTS: CDP-choline (1, 2.5, 5 mu mol; intraplantar) increased the mechanical paw withdrawal threshold and decreased paw edema in a dose- and time-dependent manner in the carrageenan-injected hindpaw. CDP-choline administration to the noninflamed contralateral hindpaw did not alter ipsdateral inflammation. Methyllycaconitine (100 nmol), a selective alpha 7nAChR antagonist, completely blocked the effects of CDP-choline when administered to the inflamed hindpaw. However, the administration of methyllycaconitine to the contralateral hindpaw did not block the effects of CDP-choline in the ipsilateral paw. The administration of CDP-choline (5 mu mol) 10 min after carrageenan administration to the ipsilateral hindpaw did not reduce swelling and edema but did significantly reduce hypersensitivity. Treatment with CDP-choline decreased tumor necrosis factor-a production in the rat paw tissue after carrageenan. CONCLUSIONS: The results of this study suggest that intraplantar CDP-choline has antihypersensitivity and antiinflammatory effects mediated via alpha 7nAChRs in the carrageenan-induced inflammatory pain model. | |
dc.description.sponsorship | United States Department of Health & Human Services National Institutes of Health (NIH) - USA (NS048158) | |
dc.description.sponsorship | United States Department of Health & Human Services National Institutes of Health (NIH) - USA (GM48085) | |
dc.description.sponsorship | Fulbright Commission Turkey | |
dc.description.sponsorship | United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of General Medical Sciences (NIGMS) (R01GM048085) | |
dc.description.sponsorship | United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of General Medical Sciences (NIGMS) (R37GM048085) | |
dc.identifier.citation | Gürün, M. S. vd. (2009). "The effect of peripherally administered cdp-choline in an acute inflammatory pain model: The role of α7 nicotinic acetylcholine receptor". Anesthesia and Analgesia, 108(5), 1680-1687. | |
dc.identifier.endpage | 1687 | |
dc.identifier.issn | 0003-2999 | |
dc.identifier.issue | 5 | |
dc.identifier.pubmed | 19372354 | |
dc.identifier.scopus | 2-s2.0-65349139499 | |
dc.identifier.startpage | 1680 | |
dc.identifier.uri | https://doi.org/10.1213/ane.0b013e31819dcd08 | |
dc.identifier.uri | https://journals.lww.com/anesthesia-analgesia/Fulltext/2009/05000/The_Effect_of_Peripherally_Administered.51.aspx | |
dc.identifier.uri | http://hdl.handle.net/11452/22696 | |
dc.identifier.volume | 108 | |
dc.identifier.wos | 000265422300051 | |
dc.indexed.wos | SCIE | |
dc.language.iso | en | |
dc.publisher | Lippincott Williams & Wilkins | |
dc.relation.collaboration | Yurt dışı | |
dc.relation.journal | Anesthesia and Analgesia | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Analgesic activity | |
dc.subject | Hyperalgesia | |
dc.subject | Citicoline | |
dc.subject | Responses | |
dc.subject | Neurons | |
dc.subject | Rats | |
dc.subject | Skin | |
dc.subject | Paw | |
dc.subject | Anesthesiology | |
dc.subject.emtree | Alpha 7 nicotinic acetylcholine receptor | |
dc.subject.emtree | Carrageenan | |
dc.subject.emtree | Cholinergic receptor | |
dc.subject.emtree | Citicoline | |
dc.subject.emtree | Sodium chloride | |
dc.subject.emtree | Unclassified drug | |
dc.subject.emtree | Aconitine | |
dc.subject.emtree | Alpha-bungarotoxin receptor | |
dc.subject.emtree | Analgesic agent | |
dc.subject.emtree | Antiinflammatory agent | |
dc.subject.emtree | Bungarotoxin receptor | |
dc.subject.emtree | Citicoline | |
dc.subject.emtree | Drug derivative | |
dc.subject.emtree | Methyllycaconitine | |
dc.subject.emtree | Nicotinic agent | |
dc.subject.emtree | Nicotinic receptor | |
dc.subject.emtree | Nicotinic receptor blocking agent | |
dc.subject.emtree | Tumor necrosis factor alpha | |
dc.subject.emtree | Animal experiment | |
dc.subject.emtree | Animal model | |
dc.subject.emtree | Article | |
dc.subject.emtree | Controlled study | |
dc.subject.emtree | Drug dose comparison | |
dc.subject.emtree | Inflammation | |
dc.subject.emtree | Macrophage | |
dc.subject.emtree | Male | |
dc.subject.emtree | Nonhuman | |
dc.subject.emtree | Pain | |
dc.subject.emtree | Paw edema | |
dc.subject.emtree | Priority journal | |
dc.subject.emtree | Rat | |
dc.subject.emtree | Animal | |
dc.subject.emtree | Chemically induced disorder | |
dc.subject.emtree | Disease model | |
dc.subject.emtree | Dose response | |
dc.subject.emtree | Drug effect | |
dc.subject.emtree | Edema | |
dc.subject.emtree | Inflammation | |
dc.subject.emtree | Injection | |
dc.subject.emtree | Metabolism | |
dc.subject.emtree | Pain | |
dc.subject.emtree | Pain assessment | |
dc.subject.emtree | Pain threshold | |
dc.subject.emtree | Sprague Dawley rat | |
dc.subject.emtree | Time | |
dc.subject.mesh | Aconitine | |
dc.subject.mesh | Analgesics | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Anti-inflammatory agents | |
dc.subject.mesh | Carrageenan | |
dc.subject.mesh | Cytidine diphosphate choline | |
dc.subject.mesh | Disease models, animal | |
dc.subject.mesh | Dose-response relationship, drug | |
dc.subject.mesh | Edema | |
dc.subject.mesh | Inflammation | |
dc.subject.mesh | Injections | |
dc.subject.mesh | Male | |
dc.subject.mesh | Nicotinic antagonists | |
dc.subject.mesh | Pain | |
dc.subject.mesh | Pain measurement | |
dc.subject.mesh | Pain threshold | |
dc.subject.mesh | Rats | |
dc.subject.mesh | Rats, sprague-dawley | |
dc.subject.mesh | Receptors, nicotinic | |
dc.subject.mesh | Time factors | |
dc.subject.mesh | Tumor necrosis factor-alpha | |
dc.subject.mesh | Nicotinic agonists | |
dc.subject.scopus | Citicoline; Neuroprotective Agents; Glycerylphosphorylcholine | |
dc.subject.wos | Anesthesiology | |
dc.title | The effect of peripherally administered cdp-choline in an acute inflammatory pain model: The role of α7 nicotinic acetylcholine receptor | |
dc.type | Article | |
dc.wos.quartile | Q1 | |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültesi/Farmakoloji ve Klinik Farmakoloji Ana Bilim Dalı | |
local.indexed.at | Scopus | |
local.indexed.at | WOS |
Files
License bundle
1 - 1 of 1
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: